Tag: Antiviral medications

In late 2021, the U.S. Food and Drug Administration (FDA) authorized the first oral antiviral treatments for COVID-19, Paxlovid and Lagevrio, for high-risk patients to help prevent severe illness. Understanding **what is the difference between Paxlovid and Lagevrio** is crucial for patients, as these medications vary significantly in their mechanisms of action, overall effectiveness, potential for drug interactions, and eligibility criteria.

As of early 2024, COVID-19 continues to impact global health, and antiviral treatments like remdesivir remain a key tool in managing the disease. Understanding who qualifies for remdesivir is essential for ensuring appropriate and timely treatment.

While tenofovir is a highly effective antiviral drug, its different formulations have distinct safety profiles. A key question for patients and clinicians is which of the following side effects is common with tenofovir, particularly when comparing the older tenofovir disoproxil fumarate (TDF) and the newer tenofovir alafenamide (TAF). The answer depends heavily on the specific formulation and individual patient factors.

Unlike its topical counterpart, oral acyclovir is not available over-the-counter (OTC) in the United States and requires a doctor's prescription for the treatment of herpes simplex, shingles, and chickenpox. This is a critical distinction that ensures proper medical diagnosis, safe use, and effective management of viral infections.

While generally considered safe and well-tolerated, rare but serious central nervous system (CNS) side effects, including neurotoxicity, have been reported in patients asking **can valacyclovir affect the brain**. This is particularly relevant for those with pre-existing kidney issues or advanced age.